- Issuer ticker
-
N/A
- Reported as of
-
25 Feb 2026
- Net transaction value
-
$0
- SEC form
-
4
- Accepted by SEC
-
26 Feb 2026, 21:11:48 UTC
Filing notes and source
Key filing fact
Lisa French filed Form 4 for Keenova Therapeutics plc on 26 Feb 2026.
Key facts
- This page summarizes Lisa French's Form 4 filing for Keenova Therapeutics plc.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Feb 2026, 21:11.
Change
- Previous filing in this sequence was filed on 05 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001948055
Primary reporting owner
French Lisa
- Relationship
-
EVP & Chief Commercial Officer
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +51,794
- Change %
- +113%
- Price
-
$0.000000
- Shares after
- 97,825
- Date
- 25 Feb 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 51,794
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Explanation of responses
2 footnotes
SEC remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.